Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study

Figures

• 

  Fig. 1. Change from baseline in morning home BP levels at EOT in the total population (a) and urinary albumin-to-creatinine ratio subcohorts (b), and change from baseline in bedtime home BP level (c) and office BP level (d) (full analysis set). Patients with a urinary albumin-to-creatinine ratio of < 30 mg/gCr, 30 to < 300 mg/gCr, and 300 to < 1000 mg/gCr were assigned to the A1, A2, and A3 subcohorts, respectively. Data are mean [95% confidence interval]. **p < 0.001. BP blood pressure, DBP diastolic blood pressure, EOT end of treatment, SBP systolic blood pressure

• 

  Fig. 2. Time course changes (a) and change from baseline (b) in morning home SBP and DBP throughout the study period (full analysis set). Data are mean ± standard deviation. **p < 0.001. BP blood pressure, DBP diastolic blood pressure, EOT end of treatment, SBP systolic blood pressure

• 

  Fig. 3. Geometric percentage change in UACR from baseline to EOT in the total population (a) and UACR subcohorts (b) (full analysis set). Patients with a UACR of < 30 mg/gCr, 30 to < 300 mg/gCr and 300 to < 1000 mg/gCr were assigned to the A1, A2, and A3 subcohorts, respectively. Error bars indicate 95% confidence intervals. **p < 0.001. EOT end of treatment, UACR urinary albumin-to-creatinine ratio

• 

  Fig. 4. Time course changes in eGFRcreat (a, b) and serum potassium levels (c, d) during the study period in the total population (a, c) and urinary albumin-to-creatinine ratio subcohorts (b, d) (safety analysis set). Patients with a urinary albumin-to-creatinine ratio of < 30 mg/gCr, 30 to < 300 mg/gCr, and 300 to < 1000 mg/gCr were assigned to the A1, A2, and A3 subcohorts, respectively. Data are mean ± standard deviation. eGFRcreat creatinine-based estimate of the glomerular filtration rate